31 August 2020>: Database Analysis
Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma
Dehua Zhang 1ACD , Muchun Zhang 2B , Qifu Zhang 3DF , Zhiyi Zhao 3BCF , Yong Nie 1ADE*DOI: 10.12659/MSM.924543
Med Sci Monit 2020; 26:e924543
Table 1 Baseline information of patients diagnosed with PRAD.
Variables | Total patients (N=500) |
---|---|
Mean±SD | 61.01±6.82 |
Median (range) | 61 (41–78) |
Female | 0 (0.00%) |
Male | 500 (100.00%) |
T2a | 13 (2.60%) |
T2b | 10 (2.00%) |
T2c | 165 (33.00%) |
T3a | 159 (31.80%) |
T3b | 136 (27.20%) |
T4 | 10 (2.00%) |
Unknown | 7 (1.40%) |
N0 | 348 (69.60%) |
N1 | 79 (15.80%) |
Unknown | 73 (14.60%) |
Adenocarcinoma, NOS | 487 (97.40%) |
Adenocarcinoma with mixed subtypes | 3 (0.60%) |
Infiltrating duct carcinoma, NOS | 9 (1.80%) |
Mucinous adenocarcinoma | 1 (0.20%) |
6 | 45 (9.00%) |
7 | 250 (50.00%) |
8 | 64 (12.80%) |
9 | 137 (27.40%) |
10 | 4 (0.80%) |
Mean±SD | 1.86±3.39 |
Median (range) | 0.10 (0.01–323.00) |
Unknown | 84 (16.80%) |
PRAD – prostate adenocarcinoma; SD – standard deviation; NOS – not otherwise specified; PSA – prostate-specific antigen. |